Compass Pathways (NASDAQ:CMPS) operates in the field of mental health care, specializing in developing innovative therapies to address a range of mental health conditions. The company is particularly focused on exploring the potential of psilocybin therapy for treatment-resistant depression, a significant and growing challenge in mental health care. Compass Pathways is actively engaged in clinical trials and research projects aimed at understanding and harnessing the therapeutic benefits of psychedelics. Their objective is to revolutionize the approach to mental health treatment, making effective and innovative therapies accessible to those in need. Compass Pathways is dedicated to improving patient outcomes and advancing mental health care through scientific research and development.